Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Change in Account Payables (2019 - 2025)

Historic Change in Account Payables for Madrigal Pharmaceuticals (MDGL) over the last 14 years, with Q3 2025 value amounting to $6.0 million.

  • Madrigal Pharmaceuticals' Change in Account Payables fell 8387.7% to $6.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.0 million, marking a year-over-year decrease of 10689.91%. This contributed to the annual value of $15.6 million for FY2024, which is 26954.87% up from last year.
  • According to the latest figures from Q3 2025, Madrigal Pharmaceuticals' Change in Account Payables is $6.0 million, which was down 8387.7% from -$4.1 million recorded in Q2 2025.
  • Madrigal Pharmaceuticals' Change in Account Payables' 5-year high stood at $37.0 million during Q3 2024, with a 5-year trough of -$11.7 million in Q1 2023.
  • Over the past 5 years, Madrigal Pharmaceuticals' median Change in Account Payables value was $1.4 million (recorded in 2022), while the average stood at $2.3 million.
  • Per our database at Business Quant, Madrigal Pharmaceuticals' Change in Account Payables skyrocketed by 546349.21% in 2021 and then plummeted by 93592.86% in 2023.
  • Quarter analysis of 5 years shows Madrigal Pharmaceuticals' Change in Account Payables stood at $11.0 million in 2021, then plummeted by 51.93% to $5.3 million in 2022, then skyrocketed by 118.24% to $11.5 million in 2023, then plummeted by 120.58% to -$2.4 million in 2024, then skyrocketed by 351.84% to $6.0 million in 2025.
  • Its Change in Account Payables stands at $6.0 million for Q3 2025, versus -$4.1 million for Q2 2025 and -$1.5 million for Q1 2025.